Academic Journal
IL1RAP promotes EMT and metastatic phenotypes in papillary thyroid carcinoma and is associated with PI3K/AKT signaling activation.
| Τίτλος: | IL1RAP promotes EMT and metastatic phenotypes in papillary thyroid carcinoma and is associated with PI3K/AKT signaling activation. |
|---|---|
| Συγγραφείς: | Zhao Y; Department of General Surgery, Chifeng Municipal Hospital, Inner Mongolia Medical University, No. 1 Zhaowuda Road, Hongshan District, Chifeng, Inner Mongolia, 024000, P.R. China., Shao Y; Department of General Surgery, Chifeng Municipal Hospital, Inner Mongolia Medical University, No. 1 Zhaowuda Road, Hongshan District, Chifeng, Inner Mongolia, 024000, P.R. China.; Baotou Medical College, No. 31 Jianshe Road, Donghe District, Baotou, Inner Mongolia, 014000, P.R. China., Guo Z; Department of General Surgery, Chifeng Municipal Hospital, Inner Mongolia Medical University, No. 1 Zhaowuda Road, Hongshan District, Chifeng, Inner Mongolia, 024000, P.R. China., Guo M; Department of General Surgery, Chifeng Municipal Hospital, Inner Mongolia Medical University, No. 1 Zhaowuda Road, Hongshan District, Chifeng, Inner Mongolia, 024000, P.R. China. myguo@cmu.edu.cn.; Research Institute of General Surgery, Affiliated Jinling Hospital of Medical School, Nanjing University, No. 305 Zhongshan East Road, Xuanwu District, Nanjing, Jiangsu, 210008, P.R. China. myguo@cmu.edu.cn. |
| Πηγή: | Medical oncology (Northwood, London, England) [Med Oncol] 2026 Oct 20; Vol. 43 (11). Date of Electronic Publication: 2026 Oct 20. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Springer Country of Publication: United States NLM ID: 9435512 Publication Model: Electronic Cited Medium: Internet ISSN: 1559-131X (Electronic) Linking ISSN: 13570560 NLM ISO Abbreviation: Med Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2011- : New York : Springer Original Publication: Northwood, Middlesex, England : Science and Technology Letters, c1994- |
| Ιατρικοί όροι (MeSH): | Proto-Oncogene Proteins c-akt*/metabolism , Thyroid Cancer, Papillary*/pathology , Thyroid Cancer, Papillary*/metabolism , Thyroid Cancer, Papillary*/genetics , Thyroid Neoplasms*/pathology , Thyroid Neoplasms*/metabolism , Thyroid Neoplasms*/genetics , Phosphatidylinositol 3-Kinases*/metabolism , Interleukin-1 Receptor Accessory Protein*/metabolism , Interleukin-1 Receptor Accessory Protein*/genetics , Epithelial-Mesenchymal Transition*, Biomarkers, Tumor/metabolism ; Humans ; Signal Transduction ; Female ; Male ; Cell Proliferation ; Cell Movement ; Prognosis ; Cell Line, Tumor ; Middle Aged ; Phenotype ; Gene Expression Regulation, Neoplastic ; Lymphatic Metastasis |
| Περίληψη: | Although papillary thyroid carcinoma (PTC) usually follows an indolent course, lymph node metastasis and locally advanced disease remain clinically important challenges. This study evaluated interleukin-1 receptor accessory protein (IL1RAP) in PTC using pan-cancer datasets, TCGA/GEO thyroid cancer cohorts, and in vitro validation. IL1RAP was upregulated in PTC tissues and cell lines, and higher IL1RAP expression was associated with advanced pathologic stage, lymph node metastasis, extrathyroidal extension, and unfavorable prognostic indicators. Functional assays showed that IL1RAP overexpression increased PTC cell proliferation, migration, invasion, and EMT-like changes, whereas transient IL1RAP silencing produced the opposite pattern. Bioinformatic enrichment and western blot analyses indicated that these cellular effects were accompanied by increased p-AKT with minimal change in total AKT, suggesting possible involvement of PI3K/AKT-related signaling. To our knowledge, this is the first systematic analysis linking IL1RAP to EMT-associated aggressive behavior in PTC. IL1RAP may represent a candidate biomarker associated with aggressive clinicopathological features, while its diagnostic/prognostic utility and therapeutic potential require further validation. (© 2026. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
| Competing Interests: | Declarations. Ethics approval and consent to participate: This study used publicly available datasets containing de-identified human tumor data. No personal identifying information was accessed or disclosed. The experimental component was approved by the Ethics Committee of Chifeng Hospital. The authors used language-editing assistance to improve readability and subsequently reviewed and edited all content; the authors take full responsibility for the final manuscript. Conflict of interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Competing interests: The authors declare no competing interests. |
| References: | Guo Z, Ge M, Chu YH, Asioli S, Lloyd RV. Recent advances in the classification of low-grade papillary-like thyroid neoplasms and aggressive papillary thyroid carcinomas: evolution of diagnostic criteria. Adv Anat Pathol. 2018;25:263–72. (PMID: 10.1097/PAP.000000000000019829762157) Vayisoglu Y, Ozcan C. Involvement of level IIb lymph node metastasis and dissection in thyroid cancer. Gland Surg. 2013;2:180–5. (PMID: 250834814115757) Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA, et al. 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid. 2025;35:841–985. (PMID: 10.1177/105072562513631204084437013090833) Guo M, Wang L, Huang Y, et al. Identification of core genes associated with lymph node metastasis and distant metastasis in papillary thyroid carcinoma based on weighted gene co-expression network analysis. Mod Oncol. 2022;30:402–7. (In Chinese). Sigarteu Chindris AM, Rivera M, Ma Y, Nair A, Liu Y, Wang X, Necela BM, et al. BRAFV600E/pTERT double mutated papillary thyroid cancers exhibit immune gene suppression. Front Endocrinol. 2024;15:1440722. (PMID: 10.3389/fendo.2024.1440722) Li B, Cai Z, Zhang Y, Chen R, Tang S, Kong F, Li W, Ding L. Biomarkers associated with papillary thyroid carcinoma and Hashimoto’s thyroiditis: bioinformatic analysis and experimental validation. Int Immunopharmacol. 2024;143:113532. (PMID: 10.1016/j.intimp.2024.11353239510033) Xin L, Li C, Ni H, Fu G, Qin Q, Zhang L. Clinical value of SPP1 overexpression in patients with papillary thyroid carcinoma. Transl Cancer Res. 2025;14:4100–14. (PMID: 10.21037/tcr-2024-25684079216712335683) Nhung LTT, Hoan NX, Giang DP, Dung DT, Phuong NT, Hanh NTM, Khanh LV, Hang NT. Prognostic significance of BRAF V600E and TERT promoter mutations in radioiodine resistance and recurrence of differentiated thyroid cancer. Med (Baltim). 2025;104:e44540. (PMID: 10.1097/MD.0000000000044540) Métois A, Bordeleau M-E, Theret L, Hajmirza A, Moujaber O, Spinella J-F, Chagraoui J, Mayotte N, Boivin I, Audemard É, et al. IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia. Biomark Res. 2025;13:61. (PMID: 10.1186/s40364-025-00769-z4022990411995633) Lv Q, Xia Q, Li A, Wang Z. The potential role of IL1RAP on tumor microenvironment-related inflammatory factors in stomach adenocarcinoma. Technol Cancer Res Treat. 2021;20:1533033821995282. (PMID: 10.1177/1533033821995282336020467897808) Gronberg C, Rattik S, Tran-Manh C, et al. Combined inhibition of IL-1, IL-33 and IL-36 signalling by targeting IL1RAP ameliorates skin and lung fibrosis in preclinical models of systemic sclerosis. Ann Rheum Dis. 2024;83:1156–68. (PMID: 10.1136/ard-2023-2251583859405811420747) Zarezadeh Mehrabadi A, Shahba F, Khorramdelazad H, Aghamohammadi N, Karimi M, Bagherzadeh K, Khoshmirsafa M, Massoumi R, Falak R. Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies. Crit Rev Oncol Hematol. 2024;193:104200. https://doi.org/10.1016/j.critrevonc.2023.104200 . (PMID: 10.1016/j.critrevonc.2023.10420037981104) Askmyr M, Agerstam H, Hansen N, et al. Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood. 2013;121:3709–13. (PMID: 10.1182/blood-2012-09-45893523479569) Warda W, Larosa F, Neto Da Rocha M, et al. CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor-engineered T cells. Cancer Res. 2019;79:663–75. (PMID: 10.1158/0008-5472.CAN-18-107830514753) Jung EJ, Jo JH, Uwamahoro C, Chae JB, Park JS, et al. Ritonavir has reproductive toxicity depending on disrupting PI3K/PDK1/AKT signaling pathway. Toxics. 2024;12:1. (PMID: 10.3390/toxics12010073) Deng Y, Lei Y, Ou Y, Li J, Hu X, Wen L, Hou K. miR-34c-3p promotes osteogenic differentiation of BMSCs by inhibiting DCBLD2 activation of the PI3K/AKT signaling pathway. J Mol Histol. 2026;57:86. (PMID: 10.1007/s10735-026-10747-w41721921) Du H, You L, Wu A, Wang F, Yu J, Chen C. Resolvin D1 inhibits IL-6-induced epithelial-mesenchymal transition of colorectal cancer cells by targeting IL-6/STAT3 signaling. Cell Biochem Biophys. 2024;82:1453–61. (PMID: 10.1007/s12013-024-01299-538740668) Noorolyai S, Shajari N, Baghbani E, Sadreddini S, Baradaran B. The relation between PI3K/AKT signalling pathway and cancer. Gene. 2019;698:120–8. (PMID: 10.1016/j.gene.2019.02.07630849534) Zhou J, Xiang W, Zhang K, Zhao Q, Xu Z, Li Z. IL1RAP knockdown in LPS-stimulated normal human astrocytes suppresses LPS-induced reactive astrogliosis and promotes neuronal cell proliferation. Neurochem Res. 2023;48:1468–79. (PMID: 10.1007/s11064-022-03811-w36502418) Zhang J, Zhang N, Fu X, et al. Bioinformatic analysis of cancer-associated fibroblast related gene signature as a predictive model in clinical outcomes and immune characteristics of gastric cancer. Ann Transl Med. 2022;10:698. (PMID: 10.21037/atm-22-2810358455279279800) Sun J, Meng M. Chemoprotective effect of scutellarin against gastric cancer in rats: an in vitro and in vivo study. J Oleo Sci. 2022;71:1003–12. (PMID: 10.5650/jos.ess2139935781253) Sun Y, Zhang Y, Gan J, et al. Comprehensive quantitative radiogenomic evaluation reveals novel radiomic subtypes with distinct immune pattern in glioma. Comput Biol Med. 2024;177:108636. (PMID: 10.1016/j.compbiomed.2024.10863638810473) Wu K, Qiu C, Ma Q, Chen F, Lu T. The anti-cancer mechanism of celastrol by targeting JAK2/STAT3 signaling pathway in gastric and ovarian cancer. Toxicol Appl Pharmacol. 2024;491:117077. (PMID: 10.1016/j.taap.2024.11707739181414) Huang H, Ma J, Cui H, Liang T, Ma Q. Identification of biomarkers for cervical cancer radiotherapy sensitivity and survival prognosis. Oncol Res Treat. 2025;48:197–211. (PMID: 10.1159/00054340939761669) Wang Y, Zhang Y, Li Y, Ma H, Zhao J, Ismtula D, Guo C. The value of Protein Phosphatase Methylesterase 1 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to breast cancer verification. Front. Immunol. 2026, 17, 1770711. https://doi.org/10.3389/fimmu.2026.1770711 . PMID: 41884849. Gou Y, Li Y, Wang Y, Ma H, Li H, Geni R, Ismtula D, Guo C. Integrated Pan-Cancer Profiling and Breast Cancer Validation Identify BEND3 as a Potential Prognostic and Immune Biomarker. Breast Cancer: Targets and Therapy 2025, 17, 1439–1461. https://doi.org/10.2147/BCTT.S553681 . PMID: 41497890. Wang J, Wang Y, Ma H, Li Y, Hou J, Li J, Ismtula D, Guo C. CLIC6’s role in cancer: from broad analysis to breast cancer validation. Front. Oncol. 2025, 15, 1667589. https://doi.org/10.3389/fonc.2025.1667589 . PMID: 41142627. Elihamu D, Li Y, Wang Y, Cui H, Xing Y, Peng H, Ismtula D, Guo C. CORO1A: a pan-cancer prognosis, diagnostic and immune biomarker based on breast cancer validation. Front. Oncol. 2025, 15, 1670526. https://doi.org/10.3389/fonc.2025.1670526 . PMID: 41122645. Song W, Liu Z, Shi C, Wang G, He L, Chen Z, Li Y, Yu Y. RAN-S100A10-EGFR axis facilitates papillary thyroid cancer metastasis by PI3K/AKT signaling. Cell Death Dis. 2026;17:1. (PMID: 10.1038/s41419-026-08649-6) Yu Y, Wang Y, Su X, Cai Z, Wang Q, Wang C, Zhao Y, Zhang T. PFOS exposure at environmentally relevant concentrations promotes papillary thyroid carcinoma progression through PI3K/AKT/mTOR-mediated epithelial-mesenchymal transition. Environ Res. 2026;297:124072. (PMID: 10.1016/j.envres.2026.12407241771471) Jia L, Han Y, Chen Z, Wang Y, Zhao K, He X. Milk fat globule-EGF factor 8 enhances the proliferation and migration of thyroid carcinoma cells through epithelial-mesenchymal transition and PI3K/AKT signaling pathway. World J Surg Oncol. 2026;24:1. (PMID: 10.1186/s12957-026-04242-5) |
| Grant Information: | grant numbers: YKD2023LH015 Joint Project of Inner Mongolia Medical University |
| Contributed Indexing: | Keywords: IL1RAP; Biomarker; Epithelial-mesenchymal transition; Immune infiltration; Metastasis; PI3K/AKT signaling; Papillary thyroid carcinoma |
| Substance Nomenclature: | EC 2.7.11.1 (Proto-Oncogene Proteins c-akt) EC 2.7.1.- (Phosphatidylinositol 3-Kinases) 0 (Interleukin-1 Receptor Accessory Protein) 0 (IL1RAP protein, human) 0 (Biomarkers, Tumor) |
| Entry Date(s): | Date Created: 20261020 Date Completed: 20261020 Latest Revision: 20261020 |
| Update Code: | 20261021 |
| DOI: | 10.1007/s12032-026-03453-w |
| PMID: | 42900448 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1559-131X |
|---|---|
| DOI: | 10.1007/s12032-026-03453-w |